pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2630Research ArticleОБЗОРЫREVIEWФорадил в терапии ХОБЛ: результаты клинических исследованийForadil in therapy of COPD: results of clinical trialsКалмановаЕ. Н.KalmanovaE. N.
Москва
АйсановЗ. Р.AisanovZ. R.
Москва
НИИ пульмонологии Минздрава РФRussian Federation20030309202105115122Copyright © Калманова Е.Н., Айсанов З.Р., 20212021Калманова Е.Н., Айсанов З.Р.Kalmanova E.N., Aisanov Z.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2630
.
ReferencesAmerican Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 1995; 152: S77-S120.American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 1995; 152: S77-S120.Appleton S., Smith B., Veale A., Bara A. Long-acting P2-agonists for COPD (Cochrane review). In: The Cochrane Library. Oxford, UK: Update Software; 2000; issue 3. Available from http://www.update-software.com/clibng/cliblogon.htm.Appleton S., Smith B., Veale A., Bara A. Long-acting P2-agonists for COPD (Cochrane review). In: The Cochrane Library. Oxford, UK: Update Software; 2000; issue 3. Available from http://www.update-software.com/clibng/cliblogon.htm.Benhamou D., Muir J.-F., Leclerc V. et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer®) with salbutamol (Ventodisk™). Respir. Med. 2001; 95: 817-821.Benhamou D., Muir J.-F., Leclerc V. et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer®) with salbutamol (Ventodisk™). Respir. Med. 2001; 95: 817-821.British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl.): S1-S28.British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl.): S1-S28.Cazzola M ., Santangelo G., Piccolo A. et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. 1994; 7: 103-107.Cazzola M ., Santangelo G., Piccolo A. et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. 1994; 7: 103-107.Cazzola M., Matera M.G., Santangelo G. et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir. Med. 1995; 89: 357-362.Cazzola M., Matera M.G., Santangelo G. et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir. Med. 1995; 89: 357-362.Cazzola M., Imperatore F., Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411-415.Cazzola M., Imperatore F., Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411-415.Cazzola M ., DiPerna F., Califano C. et al. Formoterol Turbuhaler (F) versus salmeterol Diskus (S) in patients with partially reversible stable COPD [abstr]. Am. J. Respir. Crit. Care Med. 1999; 159: A798.Cazzola M ., DiPerna F., Califano C. et al. Formoterol Turbuhaler (F) versus salmeterol Diskus (S) in patients with partially reversible stable COPD [abstr]. Am. J. Respir. Crit. Care Med. 1999; 159: A798.Cazzola M., Centanni S., Regorda C. et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm. Pharmacol. Ther. 2001; 14: 41-45.Cazzola M., Centanni S., Regorda C. et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm. Pharmacol. Ther. 2001; 14: 41-45.Cazzola M ., DiPerna F., D'Amato M . et al. Formoterol Turbuhaler® for as-needed therapy in patients with mild acute exacerbations of COPD. Respir. Med. 2001; 95: 917-921.Cazzola M ., DiPerna F., D'Amato M . et al. Formoterol Turbuhaler® for as-needed therapy in patients with mild acute exacerbations of COPD. Respir. Med. 2001; 95: 917-921.Celik G., Kayacan O., Beder S. et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66: 434-439.Celik G., Kayacan O., Beder S. et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66: 434-439.Cordina M ., Cacciottolo J.M., Jones C.H., Saliba N. Healthrelated quality of life (HRQL) and the use of formoterol in patients with COPD [abstr]. Eur. Respir. J. 2001; 18 (suppl.33): 55s.Cordina M ., Cacciottolo J.M., Jones C.H., Saliba N. Healthrelated quality of life (HRQL) and the use of formoterol in patients with COPD [abstr]. Eur. Respir. J. 2001; 18 (suppl.33): 55s.Dahl R., Kristufek P., Greefhorst A.P.M . et al. The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD [abstr]. Ibid. 2000; 16 (suppl.31): 51s.Dahl R., Kristufek P., Greefhorst A.P.M . et al. The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD [abstr]. Ibid. 2000; 16 (suppl.31): 51s.Dahl R., Greefhorst L.A.P.M., Nowak D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784.Dahl R., Greefhorst L.A.P.M., Nowak D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784.DiBartolio C.G., Gonzalez J.G., Ruggieri M .P. et al. Evaluation of the effectiveness and acceptability of Foradil®Aerolizer™ and Oxis Turbuhaler® in asthmatics. In: Program and abstracts of the 96th International conference of the American Thoracic Society. Toronto, Ontario; 2000. Session A21.DiBartolio C.G., Gonzalez J.G., Ruggieri M .P. et al. Evaluation of the effectiveness and acceptability of Foradil®Aerolizer™ and Oxis Turbuhaler® in asthmatics. In: Program and abstracts of the 96th International conference of the American Thoracic Society. Toronto, Ontario; 2000. Session A21.D'U rzo A.D., De Salvo M.C., Ramirez A. et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119 (5): 1347-1356.D'U rzo A.D., De Salvo M.C., Ramirez A. et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119 (5): 1347-1356.ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1398-1420.ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1398-1420.Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (executive summary). Bethesda, MD: National Institutes of Health; 2003.Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (executive summary). Bethesda, MD: National Institutes of Health; 2003.Guyatt G., Townsend M ., Keller J. et al. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir. Med. 1991; 85 (suppl.B): 17-21.Guyatt G., Townsend M ., Keller J. et al. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir. Med. 1991; 85 (suppl.B): 17-21.Hacki M.A., Hitiz G.W., Medici T.C. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin. Drug Invest. 1997; 14: 165-174.Hacki M.A., Hitiz G.W., Medici T.C. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin. Drug Invest. 1997; 14: 165-174.Johnson M ., Rennard S. Alternative mechanisms of long-acting (32-adrenergic agonists in COPD. Chest 2001; 120: 258-270.Johnson M ., Rennard S. Alternative mechanisms of long-acting (32-adrenergic agonists in COPD. Chest 2001; 120: 258-270.Kalmanova E.N., Stulova O.Y., Aisanov Z.R. Influence of longacting p2-agonist and sustained-release theophylline on maximal exercise capacity and endurance time in asthmatic patients. Eur. Respir. J. 2003; 22 (suppl.35) (in press).Kalmanova E.N., Stulova O.Y., Aisanov Z.R. Influence of longacting p2-agonist and sustained-release theophylline on maximal exercise capacity and endurance time in asthmatic patients. Eur. Respir. J. 2003; 22 (suppl.35) (in press).Kottakis J., Cioppa G.D., Creemers J. et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. J. 2002; 9: 107-115.Kottakis J., Cioppa G.D., Creemers J. et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. J. 2002; 9: 107-115.Linden A., Bergendal A., Gilman A. et al. Salmeterol, formoterol, and salbutamol in the isolated guinea-pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.Linden A., Bergendal A., Gilman A. et al. Salmeterol, formoterol, and salbutamol in the isolated guinea-pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.Lotvall J., Mellen A., Arvidsson P. et al. Similar bronchodilation with formoteroldelivered by aerolizer or turbuhaler. Can. Respir. J. 1999; 6: 412-416.Lotvall J., Mellen A., Arvidsson P. et al. Similar bronchodilation with formoteroldelivered by aerolizer or turbuhaler. Can. Respir. J. 1999; 6: 412-416.Maesen B.L.P., Westermann C.J.J., Duurkens V.A.M., van den Bosch J.M .M . Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13: 1103-1108.Maesen B.L.P., Westermann C.J.J., Duurkens V.A.M., van den Bosch J.M .M . Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13: 1103-1108.Maesen F.P.V., Costongs R., Smeets S.J. et al. Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992; 101: 1376-1381.Maesen F.P.V., Costongs R., Smeets S.J. et al. Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992; 101: 1376-1381.Mahler D., Tomlinson D., Olmstead E. et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am. J. Respir. Crit. Care Med. 1995; 151: 61-65.Mahler D., Tomlinson D., Olmstead E. et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am. J. Respir. Crit. Care Med. 1995; 151: 61-65.McKay S.E., Howie C.A., Thomson A.H. et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227.McKay S.E., Howie C.A., Thomson A.H. et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227.Naline E., Zhang Y., Qian Y. et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur. Respir. J. 1994; 7: 914-920.Naline E., Zhang Y., Qian Y. et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur. Respir. J. 1994; 7: 914-920.O'Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the nonbronchodilator effects of inhaled (Vagonists in asthma. N. Engl. J. Med. 1992; 327: 1204-1208.O'Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the nonbronchodilator effects of inhaled (Vagonists in asthma. N. Engl. J. Med. 1992; 327: 1204-1208.Pauwels R.A., Buist S.A., Calverley P.M.A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD). Workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.Pauwels R.A., Buist S.A., Calverley P.M.A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD). Workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.Redelmeier D., Goldstein R., Minutes S. et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest 1996; 109: 1163-1168.Redelmeier D., Goldstein R., Minutes S. et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest 1996; 109: 1163-1168.Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Ibid. 2002; 121: 1058-1069.Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Ibid. 2002; 121: 1058-1069.Sichletidis L., Kottakis J., Marcou S. et al. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int. J. Clin. Pract. 1999; 53: 185-188.Sichletidis L., Kottakis J., Marcou S. et al. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int. J. Clin. Pract. 1999; 53: 185-188.Ziment I. Pharmacological therapy of obstructive airway disease. Clin. Chest Med. 1990; 11: 461-486.Ziment I. Pharmacological therapy of obstructive airway disease. Clin. Chest Med. 1990; 11: 461-486.
The authors declare that there are no conflicts of interest present.